Sign in

You're signed outSign in or to get full access.

Abdul Qadir Puranwala

Research Analyst at ICICI Securities

Abdulkader Puranwala is a Research Analyst at ICICI Securities, specializing in the Indian pharmaceutical and healthcare sectors. He covers leading companies such as Dr. Reddy's Laboratories, Thyrocare, Dr. Lal PathLabs, and Biocon, actively participating in their earnings calls with insightful questions on growth drivers, FDA inspections, and business performance. His career includes his current role at ICICI Securities, with prior experience referenced as Deputy Manager in some contexts, though specific start dates and previous firms are not detailed in available sources. Professional credentials such as FINRA registrations or securities licenses are not specified in public records.

Abdul Qadir Puranwala's questions to DR REDDYS LABORATORIES (RDY) leadership

Question · Q3 2026

Abdul Qadir Puranwala asked about the launch timelines for Semaglutide in India and other international markets, the current cartridge capacity, and the updated timelines and internal estimates for biosimilars like Denosumab, Rituximab, and Abatacept.

Answer

CEO Erez Israeli outlined Semaglutide launches: India on March 21st, Canada between February and May, and Brazil/Turkey around July, with registrations in over 80 markets. The current cartridge capacity is 12 million, with plans for expansion. He noted Rituximab's U.S. launch delay primarily impacts partner Fresenius, while Denosumab's U.S. approval is delayed by at least six months. Abatacept's U.S. IV approval is expected by end of calendar 2026, and sub-Q by Jan/Feb 2028, with no impact from other biosimilar issues.

Ask follow-up questions

Fintool

Fintool can predict DR REDDYS LABORATORIES logo RDY's earnings beat/miss a week before the call